5-HTR2A基因-1438A/G多态性与重性抑郁障碍及药效学作用的关联研究

目的 探讨5-HTR2A基因-1438A/G多态性(rs6315)与重性抑郁障碍(MDD)及氟西汀治疗MDD疗效的关系.方法 采用聚合酶链反应扩增技术与限制性片段长度多态性分析技术(PCR-RFLP)检测MDD患者(病例组)和正常健康者(对照组)5-HTR2A基因-1438A/G多态性的基因型和等位基因频率.氟西汀治疗MDD患者6周末,采用汉密尔顿抑郁量表(HAMD)评价疗效,分析疗效与基因型之间的关系.结果 对照组与病例组在基因型、等位基因及A等位基因携带者的分布频率间存在明显差异,有统计学意义(P＜0.05);病例组的-1438A等位基因的频率高于对照组,差异有统计学意义(P＜0.05).氟西汀治疗反应较好的MDD患者携带G/G等位基因的频率较高,差异有统计学意义(P＜0.05);治疗反应不好的MDD患者携带A等位基因的频率较高,差异有统计学意义(P＜0.05).结论 5-HTR2A基因-1438A/G多态性与MDD的发病有关,A等位基因可能是MDD发病的危险因素;5-HTR2A基因-1438A/G多态性与氟西汀的抗抑郁疗效有关,携带A等位基因的患者对氟西汀的治疗反应较差,G/G基因型的患者比A/A、A/G基因型的患者对氟西汀有更好的反应.

5-HTR2A Gene-1438AG Plymorphism and Effect of Fluoxetine in Major Depressive Disorder Patients

Objective To investigate the relation of functional polymorphism-1438AG in the promoter region of the 5-HT2A receptor gene(5-HTR2A)(rs6315)with major depressive disorder(MDD)and the therapeutic effect of Fluoxetine.Methods Genotype and allele frequencies of polymorphism-1438CG of 5-HTR2A in MDD patients and normal controls were examined by PCR-RFLP technique.After the patients accepted 6-week Fluoxetine treatment,the effect was evaluated by Hamilton Depression Rating Scale(HAMD)to analyze the relationship b...